• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板-白蛋白-胆红素与白蛋白-胆红素作为肝切除术后乙型肝炎所致肝细胞癌长期生存预测指标的比较

Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.

作者信息

Yang Haojie, Shen Shuang, Yang Yuting, Zhou Houping, Xiang Bangde

机构信息

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China.

Department of Hepatobiliary Surgery, Changde Hospital (The First People's Hospital of Changde City), Xiangya School of Medicine, Central South University, Changde, Hunan, 415000, China.

出版信息

BMC Cancer. 2025 May 12;25(1):855. doi: 10.1186/s12885-025-14240-7.

DOI:10.1186/s12885-025-14240-7
PMID:40355826
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12067726/
Abstract

BACKGROUND

The Child-Pugh (CP) score is widely used to evaluate the severity of liver dysfunction in patients with hepatocellular carcinoma (HCC). Recently, both the albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) grade have been raised to be objective measurement indexes of liver function which can sufficiently stratify HCC patient survival. In this study, we aim to compare the ability of albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) grade to predict outcomes in hepatitis B-Induced HCC after liver resection with curative intent.

METHODS

Between April 2013 and April 2023, 1005 consecutive hepatitis B-Induced HCC patients who underwent liver resection were included in this study. The performance of PALBI and ALBI score in predicting long-term survival was evaluated.

RESULTS

The area under the ROC curve (AUC) of the PALBI(AUC:0.618) for predicting long-term survival was greater than that of the ALBI(AUC:0.522). In the multivariate analysis for OS, both the ALBI (HR: 1.246 95%CI: 1.029-1.508 P = 0.024) and PALBI (HR: 1.207 95%CI: 1.049-1.388 P = 0.009) scores were identified as independent predictors of OS in HCC patients. In the univariate analysis for DFS, the PALBI grade was also significantly associated with poor DFS (P = 0.041). In contrast, the ALBI grade was not found to be significantly associated with poor DFS (P = 0.414). Subgroup analysis also showed, among patients across each BCLC stage, the group with ALBI grade 1 had DFS similar to that of the group with ALBI grade 2 (both P > 0.05). However, the PALBI grade can differentiate each BCLC stages into three prognostic groups (all P < 0.05).

CONCLUSION

Compared to ALBI grade, the PALBI grade is more clinically feasible and has better prognostic ability regardless of the grade of BCLC stage.

摘要

背景

Child-Pugh(CP)评分广泛用于评估肝细胞癌(HCC)患者肝功能障碍的严重程度。最近,白蛋白-胆红素(ALBI)分级和血小板-白蛋白-胆红素(PALBI)分级已成为肝功能的客观测量指标,可充分对HCC患者的生存进行分层。在本研究中,我们旨在比较白蛋白-胆红素(ALBI)分级和血小板-白蛋白-胆红素(PALBI)分级预测根治性肝切除术后乙型肝炎所致HCC患者预后的能力。

方法

2013年4月至2023年4月,本研究纳入了1005例连续接受肝切除的乙型肝炎所致HCC患者。评估了PALBI和ALBI评分在预测长期生存方面的性能。

结果

PALBI预测长期生存的ROC曲线下面积(AUC:0.618)大于ALBI(AUC:0.522)。在OS的多因素分析中,ALBI(HR:1.246,95%CI:1.029-1.508,P = 0.024)和PALBI(HR:1.207,95%CI:1.049-1.388,P = 0.009)评分均被确定为HCC患者OS的独立预测因素。在DFS的单因素分析中,PALBI分级也与较差的DFS显著相关(P = 0.041)。相比之下,未发现ALBI分级与较差的DFS显著相关(P = 0.414)。亚组分析还显示,在每个BCLC分期的患者中,ALBI 1级组的DFS与ALBI 2级组相似(均P > 0.05)。然而,PALBI分级可将每个BCLC分期分为三个预后组(均P < 0.05)。

结论

与ALBI分级相比,PALBI分级在临床上更可行,并且无论BCLC分期如何,都具有更好的预后能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/033e4f57214a/12885_2025_14240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/93ca470ab0d6/12885_2025_14240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/098e5b955711/12885_2025_14240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/033e4f57214a/12885_2025_14240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/93ca470ab0d6/12885_2025_14240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/098e5b955711/12885_2025_14240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9964/12067726/033e4f57214a/12885_2025_14240_Fig3_HTML.jpg

相似文献

1
Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.血小板-白蛋白-胆红素与白蛋白-胆红素作为肝切除术后乙型肝炎所致肝细胞癌长期生存预测指标的比较
BMC Cancer. 2025 May 12;25(1):855. doi: 10.1186/s12885-025-14240-7.
2
Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study.接受根治性手术治疗的Child-Pugh A级乙肝相关性肝细胞癌患者的白蛋白-胆红素及血小板-白蛋白-胆红素分级:一项回顾性观察研究
Medicine (Baltimore). 2019 Oct;98(43):e17394. doi: 10.1097/MD.0000000000017394.
3
Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study.比较不同评分系统在肝癌治疗方式中的总体生存预测价值:以血小板-白蛋白-胆红素(PALBI)和白蛋白-胆红素(ALBI)分级为重点:一项全国性队列研究。
PLoS One. 2019 May 2;14(5):e0216173. doi: 10.1371/journal.pone.0216173. eCollection 2019.
4
Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.白蛋白-胆红素及血小板-白蛋白-胆红素分级准确预测接受常规经动脉化疗栓塞术的高危肝细胞癌患者的总生存期。
J Vasc Interv Radiol. 2017 Sep;28(9):1224-1231.e2. doi: 10.1016/j.jvir.2017.05.020. Epub 2017 Jul 6.
5
ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era.在终末期肝病模型(MELD)时代,ALBI和PALBI分级可预测不同治疗方式和巴塞罗那临床肝癌(BCLC)分期的肝细胞癌患者的生存率。
J Gastroenterol Hepatol. 2017 Apr;32(4):879-886. doi: 10.1111/jgh.13608.
6
Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma.血小板-白蛋白-胆红素分级:用于肝衰竭风险分层和肝癌切除术后预后的评估。
Dig Liver Dis. 2019 Oct;51(10):1430-1437. doi: 10.1016/j.dld.2019.04.006. Epub 2019 May 1.
7
Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study.术前血小板-白蛋白-胆红素分级预测乙型肝炎病毒相关肝细胞癌患者肝切除术后的预后:一项回顾性研究
Medicine (Baltimore). 2018 Mar;97(12):e0226. doi: 10.1097/MD.0000000000010226.
8
Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.白蛋白-胆红素与 Child-Pugh 评分作为肝癌肝切除术后结局的预测指标。
Br J Surg. 2016 May;103(6):725-734. doi: 10.1002/bjs.10095. Epub 2016 Mar 23.
9
The EZ-ALBI and PALBI scores contribute to the clinical application of ALBI in predicting postoperative recurrence of HCC.EZ-ALBI评分和PALBI评分有助于ALBI在预测肝癌术后复发方面的临床应用。
Sci Rep. 2025 Mar 17;15(1):9132. doi: 10.1038/s41598-025-93716-9.
10
Modified Child-Pugh grade albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy.改良的 Child-Pugh 分级联合白蛋白-胆红素分级对预测肝癌患者肝切除术后预后的价值。
World J Gastroenterol. 2020 Feb 21;26(7):749-758. doi: 10.3748/wjg.v26.i7.749.

本文引用的文献

1
Chronological evolution in liver resection for hepatocellular carcinoma: Prognostic trends across three decades in early to advanced stages.肝细胞癌肝切除的时间演变:早期至晚期三个十年的预后趋势
Eur J Surg Oncol. 2025 Feb;51(2):109461. doi: 10.1016/j.ejso.2024.109461. Epub 2024 Nov 18.
2
Artificial intelligence-based evaluation of prognosis in cirrhosis.基于人工智能的肝硬化预后评估。
J Transl Med. 2024 Oct 14;22(1):933. doi: 10.1186/s12967-024-05726-2.
3
Survival benefit of sequential curative treatment for TACE suitable BCLC stage B HCC patients.
序贯治疗对 TACE 适宜 BCLC 期 B 肝癌患者的生存获益。
Sci Rep. 2024 Sep 29;14(1):22588. doi: 10.1038/s41598-024-72767-4.
4
Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma.香港肝癌巴塞罗那临床肝癌分期系统在肝细胞癌中的预后性能。
BMC Gastroenterol. 2024 Sep 18;24(1):318. doi: 10.1186/s12876-024-03387-5.
5
Recurrence of Hepatocellular Carcinoma in Patients with Low Albumin-Bilirubin Grade in TACE Combined with Ablation: A Random Forest Cox Predictive Model.TACE联合消融治疗的低白蛋白-胆红素分级患者肝细胞癌的复发:随机森林Cox预测模型
J Hepatocell Carcinoma. 2024 Jul 8;11:1375-1388. doi: 10.2147/JHC.S465962. eCollection 2024.
6
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
7
Comparison of post-resection survival between hepatocellular carcinoma patients in BCLC stage A or B who experience tumor rupture and patients in BCLC stage C who do not.BCLC A期或B期肝细胞癌出现肿瘤破裂的患者与BCLC C期未出现肿瘤破裂的患者术后生存率的比较。
Heliyon. 2024 Feb 29;10(5):e27355. doi: 10.1016/j.heliyon.2024.e27355. eCollection 2024 Mar 15.
8
A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage.一种新模型用于估算 BCLC 中期肝细胞癌患者的生存持续时间。
Sci Rep. 2023 Nov 25;13(1):20739. doi: 10.1038/s41598-023-48068-7.
9
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).原发性肝癌诊疗指南(2022年版)
Liver Cancer. 2023 Apr 5;12(5):405-444. doi: 10.1159/000530495. eCollection 2023 Oct.
10
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.